Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies - Wikidata - wikimedia - TriplyDB

Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies

Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies

http://www.wikidata.org/entity/Q28074637

about

Relationship Between Antihypertensive Medications and Cognitive Impairment: Part II. Review of Physiology and Animal Studies

http://www.wikidata.org/entity/Q28074637

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Relationship Between Antihyper ...... Physiology and Animal Studies

@ast

Relationship Between Antihyper ...... Physiology and Animal Studies

@en

Relationship Between Antihyper ...... Physiology and Animal Studies

@nl

type

label

Relationship Between Antihyper ...... Physiology and Animal Studies

@ast

Relationship Between Antihyper ...... Physiology and Animal Studies

@en

Relationship Between Antihyper ...... Physiology and Animal Studies

@nl

prefLabel

Relationship Between Antihyper ...... Physiology and Animal Studies

@ast

Relationship Between Antihyper ...... Physiology and Animal Studies

@en

Relationship Between Antihyper ...... Physiology and Animal Studies

@nl

P1433

Q28074637-E24F360C-8F53-4122-873C-B35E3DB9150D

P1476

Q28074637-8EB088F8-EAEE-4E36-A52F-A778CB97E62F

P2093

Q28074637-5008F6A5-87F3-4263-98BE-30383E873C1E

Q28074637-CC3A87D4-AE33-4D66-9A49-8EE654B63AFA

Q28074637-E36E99DB-34BC-4179-BBEC-0599483C3976

Q28074637-F069AF93-21CE-4C84-8639-4A535FA3D78C

Q28074637-FDCB0B29-F601-406C-B7FD-54EE658224CD

P275

Q28074637-14F127D7-7AFD-4140-9E76-323B29E55905

P2860

Q28074637-041324D5-6E3A-4A8C-BBEE-E156832C1548

Q28074637-04DFCA3A-F713-4FCF-9DFD-1D82FEED6854

Q28074637-04E52B25-D706-4867-994E-93458FE62F72

Q28074637-07CDDFB2-8F1D-4200-9F21-BE9F590539AD

Q28074637-17CCD986-25AE-410A-BD96-ED64B961D107

Q28074637-214FF5B5-81E1-4B06-BF87-4B2AAE021364

Q28074637-26C69571-32FD-4EEE-B2E3-5782B5E6F4C7

Q28074637-2D7380FE-85C8-47FD-B630-C224502DD1C3

Q28074637-3A0A28AB-047B-46A0-BE8A-1C7E4FFF4639

Q28074637-3C90D0EE-922B-4F64-AD9E-874829142145

P2888

Q28074637-6EEB6826-B4CD-4CFD-8E84-BEECB1EE56FD

P304

Q28074637-C63CEF47-773A-4587-BC37-A2B6C9487AEA

P31

Q28074637-74C14FE2-32E8-4DEF-8241-3F738A5E23BD

Q28074637-A176CA80-BE1F-4F57-9B7A-F3C2AD3DFF41

P3181

Q28074637-75191292-276D-48D7-8E25-AA3359B710EF

P356

Q28074637-DC16175A-E36F-45A8-93BD-3C2BE6A53A49

P407

Q28074637-5D0E8248-FE7A-4E0B-AFD3-1B1D07F3C8FC

P433

Q28074637-45265F38-29B9-4927-8751-E943B7C31F7A

P478

Q28074637-B76D89AD-2EA1-454E-B98A-31B13CEDEEB3

P5008

Q28074637-DA809F1B-7F20-4CD4-9C16-986A5EFA155B

P577

Q28074637-BD298EDE-0800-461C-B182-23CE2416EBB6

Q28074637-F8BC8943-F8FC-4E17-B8CD-32A1C2135086

P6179

Q28074637-664C8B09-FF0C-42CD-84C6-809A00A65ED2

P698

Q28074637-FE27673E-4678-40FA-A889-97AB08D447F9

P921

Q28074637-7B6EB04C-0971-4990-AA33-1875D18E7B70

Q28074637-BCF6B2CA-8F87-47CE-B5B7-BD754B215D83

Q28074637-EC69B798-F0FF-42D2-AED6-6E80E720E510

P932

Q28074637-1B1307BE-00E6-467C-9B51-3A170C9D2464

P3181

P356

S11906-016-0673-2

P1433

Current Hypertension Reports

P1476

Relationship Between Antihyper ...... Physiology and Animal Studies

@en

P2093

Jean Peters

http://www.w3.org/2001/XMLSchema#string

Mattan Schuchman

http://www.w3.org/2001/XMLSchema#string

Michelle C. Carlson

http://www.w3.org/2001/XMLSchema#string

Ruth Peters

http://www.w3.org/2001/XMLSchema#string

Sevil Yasar

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Alzheimer's Disease

Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease

Nimodipine improves regional cerebral blood flow and suppresses inflammatory factors in the hippocampus of rats with vascular dementia.

Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.

Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.

Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.

Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study

Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease

Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.

Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

P2888

s11906-016-0673-2

P304

66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4377830

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S11906-016-0673-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1041611541

http://www.w3.org/2001/XMLSchema#string

P698

27492369

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

cognitive dysfunction

biomedical investigative technique

P932

4988998

http://www.w3.org/2001/XMLSchema#string